Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis
Walid Fakhouri,1 Pedro Lopez-Romero,2 Silvia Antonelli,3 Serena Losi,4 Veronica Rogai,4 Stefano Buda,5 Diego Sangiorgi,5 Valentina Perrone,5 Luca Degli Esposti5 1Eli Lilly & Company, Erl Wood, UK; 2Eli Lilly & Company, Madrid, Spain; 3Eli Lilly Italy S.p.A., Roma, I...
Guardado en:
Autores principales: | Fakhouri W, Lopez-Romero P, Antonelli S, Losi S, Rogai V, Buda S, Sangiorgi D, Perrone V, Degli Esposti L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/06221df7cf294e5fadc47b4b581f0ab7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
por: Bertoldi I, et al.
Publicado: (2021) -
The onset of rheumatoid arthritis following trauma
por: Brawer AE, et al.
Publicado: (2016) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler E, et al.
Publicado: (2021) -
Clinical and serological characteristics of Ecuadorian patients with rheumatoid arthritis
por: Ríos C, et al.
Publicado: (2017) -
Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients
por: Almalag H, et al.
Publicado: (2020)